Working… Menu

Carmustine Followed By Surgery in Treating Patients With Recurrent Supratentorial Malignant Glioma or Metastatic Brain Neoplasm

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00009854
Recruitment Status : Unknown
Verified March 2003 by National Cancer Institute (NCI).
Recruitment status was:  Active, not recruiting
First Posted : January 27, 2003
Last Update Posted : November 6, 2013
Information provided by:
National Cancer Institute (NCI)

Brief Summary:

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase I/II trial to study the effectiveness of carmustine followed by surgery in treating patients who have recurrent supratentorial malignant glioma or metastatic brain neoplasm.

Condition or disease Intervention/treatment Phase
Brain and Central Nervous System Tumors Metastatic Cancer Drug: carmustine in ethanol Procedure: conventional surgery Phase 1 Phase 2

Detailed Description:


  • Determine the extent and pattern of distribution of DNA adducts in patients with recurrent supratentorial malignant glioma or metastatic neoplasm to the brain treated with neoadjuvant intratumoral carmustine in ethanol (DTI-015) followed by tumor resection.
  • Determine the qualitative and quantitative toxicity of this treatment regimen in these patients.

OUTLINE: This is a dose escalation study.

Patients receive neoadjuvant carmustine in ethanol (DTI-015) intratumorally under stereotactic guidance 45-90 minutes prior to craniotomy and tumor resection.

Cohorts of 3-6 patients receive escalating doses of DTI-015 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 3 of 3 or 3 of 6 patients experience dose-limiting toxicity.

Patients are followed at 4, 8, and 12 weeks, and then every 3 months thereafter.

PROJECTED ACCRUAL: A total of 15 patients will be accrued for this study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Primary Purpose: Treatment
Official Title: Phase I/II Study of Intratumoral Injection of DTI-015 Prior to Tumor Resection in Patients With Recurrent Malignant Glioma or Metastatic Neoplasm to Brain
Study Start Date : June 2000

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Histologically confirmed recurrent supratentorial malignant glioma with clear evidence of progression by MRI

    • Glioblastoma multiforme
    • Anaplastic ependymoma
    • Anaplastic astrocytoma
    • Anaplastic oligodendroglioma OR
  • Metastatic tumor to the brain other than melanoma
  • Planned resection of tumor (must be first surgery for recurrent disease)
  • Tumor volume of each tumor component or residual tumor must be at least 4 cm3 and no greater than 33.4 cm3
  • Tumor shape and surrounding structure(s) unlikely to cause an irregular distribution of the injected study drug

    • Tumor is spherical, spheroid, or ovoid
    • No tumors shaped into 3 or more components (e.g., multicentric or multilobulated)
    • No tumors extending into the ventricular system
    • Tumor has an intact stroma (i.e., tumor mass not partially incised or punctured)
    • Central necrosis and/or central cystic areas allowed if an enhancing rim with a thickness of more than 5 mm is present
  • No tumors in the following locations of the brain:

    • Brainstem (pons or medulla)
    • Midbrain (mesencephalon)
    • Primary sensorimotor cortex in the dominant hemisphere
    • Within 1.5 cm of the optic chiasm, either optic nerve, or any other cranial nerve



  • 18 to 75

Performance status:

  • Karnofsky 60-100%

Life expectancy:

  • Not specified


  • Absolute neutrophil count at least 1,500/mm^3
  • Platelet count at least 100,000/mm^3
  • No evidence of bleeding diathesis


  • Bilirubin no greater than 2.0 mg/dL
  • SGOT and SGPT no greater than 2.5 times normal


  • Creatinine no greater than 2.0 mg/dL OR
  • Creatinine clearance at least 40 mL/min OR
  • BUN no greater than 30 mg/dL


  • No active uncontrolled infection
  • Afebrile (37.5 degrees C) unless fever due to tumor
  • No other unstable or severe medical condition
  • No complicating medical or psychiatric problem that would preclude study
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception


Biologic therapy:

  • Not specified


  • At least 4 weeks since prior systemic chemotherapy (6 weeks for nitrosoureas, mitomycin, or Gliadel wafers) and recovered
  • No anti-tumor chemotherapy within 12 weeks after study drug unless tumor volume increases by more than 25% by MRI

Endocrine therapy:

  • Not specified


  • At least 4 weeks since prior radiotherapy and recovered
  • No prior intracranial brachytherapy
  • No anti-tumor radiotherapy within 12 weeks after study drug unless tumor volume increases by more than 25% by MRI


  • See Disease Characteristics
  • Prior surgery allowed
  • No anti-tumor surgery within 12 weeks after study drug


  • No concurrent anticoagulants
  • No other concurrent investigational agents

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00009854

Layout table for location information
United States, California
UCSF Cancer Center and Cancer Research Institute
San Francisco, California, United States, 94143-0128
United States, Virginia
Massey Cancer Center
Richmond, Virginia, United States, 23298-0631
Sponsors and Collaborators
Direct Therapeutics
Layout table for investigator information
Study Chair: Gene David Resnick, MD Millennix
Layout table for additonal information Identifier: NCT00009854    
Other Study ID Numbers: CDR0000068416
First Posted: January 27, 2003    Key Record Dates
Last Update Posted: November 6, 2013
Last Verified: March 2003
Keywords provided by National Cancer Institute (NCI):
adult glioblastoma
tumors metastatic to brain
adult anaplastic astrocytoma
adult anaplastic ependymoma
adult anaplastic oligodendroglioma
adult giant cell glioblastoma
adult gliosarcoma
Additional relevant MeSH terms:
Layout table for MeSH terms
Nervous System Neoplasms
Central Nervous System Neoplasms
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Neoplasms by Site
Nervous System Diseases
Anti-Infective Agents, Local
Anti-Infective Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents